A vs. SNY: Agilent vs. Sanofi Stock Comparison
How do Agilent (A) and Sanofi (SNY) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Agilent (A) and Sanofi (SNY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but A is classified in Life Sciences Tools & Services while SNY is classified in Pharmaceuticals.
Agilent (A) trades as ordinary local shares, while Sanofi (SNY) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.
| Profile Item | A | SNY |
|---|---|---|
| Name | AgileThought, Inc. Class A Common Stock | Sanofi ADR |
| Country/Region | United States | France |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Life Sciences Tools & Services | Pharmaceuticals |
| GICS Sub-Industry | Life Sciences Tools & Services | Pharmaceuticals |
| Market Capitalization | 49.28 billion USD | 112.71 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | Nasdaq |
| Listing Date | November 18, 1999 | July 1, 2002 |
| Security Type | Common Stock | ADR |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | A | SNY |
|---|---|---|
| Total Return (1Y) | 22.92% | 2.73% |
| Total Return (3Y, Annualized) | 19.33% | 6.89% |
| Total Return (5Y, Annualized) | 3.03% | 3.16% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | A | SNY |
|---|---|---|
| Volatility (1Y, Annualized) | 33.10% | 23.60% |
| Beta (5Y) | 1.22 | 0.28 |
| Max Drawdown (5Y) | -38.09% | -33.52% |
| Avg. Volume (3M) | 2.25M | 3.29M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | A | SNY |
|---|---|---|
| Sharpe Ratio (1Y) | 0.56 | -0.07 |
| Sortino Ratio (1Y) | 0.96 | -0.10 |
Profitability
ROE (TTM)
Agilent (A) at 20.97% sits in the top ROE quartile, while Sanofi (SNY) at 5.72% is closer to the peer norm — stronger capital efficiency for A.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
20.97%
- Max
- 109.18%
- A
- 20.97%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
SNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.72%
- Max
- 109.18%
- Q3
- 6.23%
- SNY
- 5.72%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Agilent (A) at 19.53% keeps the most of each sales dollar — above its industry’s net margin range — and Sanofi (SNY) at 8.20% also retains a top-quartile share.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
19.53%
- A
- 19.53%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
SNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.20%
- Max
- 18.05%
- SNY
- 8.20%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Agilent (A) at 25.56% and Sanofi (SNY) at 30.89% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
25.56%
- Max
- 83.12%
- A
- 25.56%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
SNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
30.89%
- Max
- 83.12%
- SNY
- 30.89%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | A | SNY |
|---|---|---|
| ROE (TTM) | 20.97% | 5.72% |
| ROA (TTM) | 8.63% | 5.31% |
| Net Margin (TTM) | 19.53% | 8.20% |
| Operating Margin (TTM) | 25.56% | 30.89% |
| Gross Margin (TTM) | 53.65% | 73.68% |
Growth
Revenue Growth
Both Agilent (A) at 6.73% and Sanofi (SNY) at 5.49% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Both Agilent (A) at 3.16% and Sanofi (SNY) at 39.43% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.
Growth Metrics
| Metric | A | SNY |
|---|---|---|
| Revenue Growth (YoY) | 6.73% | 5.49% |
| Revenue Growth (3Y CAGR) | 0.48% | 4.82% |
| EPS Growth (YoY) | 3.16% | 39.43% |
| EPS Growth (3Y CAGR) | 3.02% | 6.02% |
Financial Strength
Current Ratio (MRQ)
Both Agilent (A) at 2.05 and Sanofi (SNY) at 1.12 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.05
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- A
- 2.05
- Min
- 0.10
SNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.12
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- SNY
- 1.12
- Min
- 0.10
Debt / Equity (MRQ)
Both Agilent (A) at 0.56 and Sanofi (SNY) at 0.27 fund their balance sheets with roughly industry-typical debt-to-equity mixes.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.56
- Max
- 1.42
- Q3
- 0.65
- A
- 0.56
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
SNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.27
- Max
- 1.42
- Q3
- 0.65
- SNY
- 0.27
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | A | SNY |
|---|---|---|
| Current Ratio (MRQ) | 2.05 | 1.12 |
| Debt / Equity (MRQ) | 0.56 | 0.27 |
| Net Debt / EBITDA | 1.15 | 0.96 |
Dividends
Dividend Yield (TTM)
Sanofi (SNY) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Agilent (A) reports a yield of 0.59%, ranking against industry peers normally.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.59%
- A
- 0.59%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
SNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- SNY
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Sanofi (SNY) reports payout ratio above 100% at 119.86%, meaning dividends exceeded current-period earnings and sustainability needs extra context. Meanwhile Agilent (A) reports 19.98%, ranking against industry peers normally.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
19.98%
- A
- 19.98%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
SNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
119.86%
- SNY
- 119.86%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | A | SNY |
|---|---|---|
| Dividend Yield (TTM) | 0.59% | 0.00% |
| Dividend Payout Ratio (TTM) | 19.98% | 119.86% |
Valuation
P/E Ratio (TTM)
Both Agilent (A) at 34.47 and Sanofi (SNY) at 23.40 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
34.47
- Max
- 85.34
- Q3
- 43.46
- A
- 34.47
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
SNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
23.40
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- SNY
- 23.40
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
Sanofi (SNY) at 2.21 sits in the cheaper P/S ratio quartile while Agilent (A) at 6.68 prices around its industry’s middle — SNY costs less per dollar of sales, though read it alongside growth and margins.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.68
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- A
- 6.68
- Q1
- 3.01
- Min
- 0.01
SNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.21
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- SNY
- 2.21
- Min
- 0.01
P/B Ratio (MRQ)
Sanofi (SNY) at 1.38 looks cheap against book in the lower P/B ratio quartile, while Agilent (A) at 6.69 carries a premium in the upper quartile — a clear price-to-book gap.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.69
- Max
- 13.53
- A
- 6.69
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
SNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.38
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- SNY
- 1.38
- Min
- -5.59
Valuation Metrics
| Metric | A | SNY |
|---|---|---|
| P/E Ratio (TTM) | 34.47 | 23.40 |
| P/S Ratio (TTM) | 6.68 | 2.21 |
| P/B Ratio (MRQ) | 6.69 | 1.38 |
| Free Cash Flow Yield (TTM) | 2.15% | 7.17% |